Hyperchloraemic metabolic acidosis.
Cholestyramine carries a risk of hyperchloraemic metabolic acidosis. Being cognisant of this drug-induced adverse event may reduce diagnostic delays. Emergency physicians should be alert about this condition, in particular among patients with pre-existing chronic kidney disease, or who are taking spironolactone.
Fan
F S Y
FS
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, SAR, China.
Chow
K M
KM
Szeto
C C
CC
Li
P K T
PK
D000138:Acidosis / Q000139:chemically induced*; D000924:Anticholesteremic Agents / Q000009:adverse effects*; D002713:Chlorine / Q000097:blood*; D002792:Cholestyramine Resin / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged
D000924:Anticholesteremic Agents; D002792:Cholestyramine Resin; D002713:Chlorine